Predicting Incidence of Dose Limiting Toxicities in Lymphoma Trials (2011 ASH...
Runtime 01:00 Show in multimedia views Clinical Director of the Lymphoma Outpatient Unit Paul Hamlin discusses relationship between DLT and SAE with increasing age and comorbidities in lymphoma...
View ArticleOfatumumab with ICE or DHAP Chemotherapy in B Cell Lymphoma (2011 ASH...
Runtime 02:00 Show in multimedia views Medical oncologist Matthew Matasar discusses the inclusion of OFA in second-line therapy for aggressive or relapsing B-cell non-Hodgkin’s lymphoma. read more
View ArticleAllogeneic Transplant Following Brentuximab Vedotin Treatment (2011 ASH...
Runtime 02:00 Show in multimedia views Clinical Director of the Division of Hematologic Oncology Craig Moskowitz discusses positive responses of brentuximab vedotin in patients with Hodgkin lymphoma...
View ArticlePegylated Liposomal Doxirubicin in Cutaneous T Cell Lymphoma (2011 ASH...
Runtime 02:00 Show in multimedia views Medical oncologist David Straus discusses how sequential bexarotene does not increase response rate in patients with Kaposi’s sarcoma. read more
View ArticleRole of FDG PET, CT, and Bone Marrow Biopsy (2011 ASH Conference)
Runtime 03:00 Show in multimedia views Chief of the Lymphoma Service Andrew Zelenetz discusses a retrospective review examining the frequency of FDG avidity across a range of lymphoma histologies....
View ArticleDeveloping New Treatments for T Cell Lymphoma
Runtime 05:00 Show in multimedia views Medical oncologist Steven M. Horwitz discusses the development and impact of three new, widely used therapies for T cell lymphoma: pralatrexate, romidepsin, and...
View ArticleClinical Trial: BMS-906024 for Relapsed or Refractory T-Cell Acute...
Runtime 02:00 Show in multimedia views Hematologist-oncologist Don Douer discusses a Phase I clinical trial of intravenous BMS-906024. read more
View ArticlePhase I Clinical Trial of Anti-PD-1 in Hematologic Malignancy
Runtime 03:00 Show in multimedia views Medical oncologist Alexander Lesokhin discusses a phase I dose escalation of an anti-PD-1 immunotherapy in patients with hematologic cancers. read more
View ArticlePredictor of Transplantation Failure in Relapsed and Refractory Follicular...
Runtime 03:00 Show in multimedia views Fellow Matthew Lunning describes a retrospective study that examined event-free and overall survival among patients with relapsed/refractory follicular lymphoma....
View Article
